Pfizer's Product Pipeline Powers Revenue Growth Despite Looming Loss of Exclusivity Challenges

Pfizer’s transformation story centers on one critical reality: its COVID-era cash cows are fading, but a robust new product arsenal is picking up the slack. While Comirnaty and Paxlovid revenues have contracted significantly from pandemic peaks, the company is banking on a diversified portfolio to maintain momentum through the LOE cliff approaching in 2026-2030.

The Growth Engines Behind PFE’s Turnaround

The real action lies in Pfizer’s non-COVID franchise. Key performers like Vyndaqel, Padcev, and Eliquis are delivering consistent growth, while the December 2023 acquisition of Seagen added serious firepower to its oncology arsenal. The Seagen deal brought four ADC (antibody-drug conjugate) therapies—Adcetris, Padcev, Tukysa, and Tivdak—that have already meaningfully bolstered 2024-2025 revenues.

Pfizer’s recent launches and acquired products grew approximately 9% operationally in the first nine months of 2025, with momentum expected to carry into 2026. The company also received nine new drug approvals in 2023 and gained approval for Hympavzi (marstacimab), a gene therapy for hemophilia, in 2024—signaling a serious commitment to diversification beyond traditional small molecules.

Despite the LOE headwinds and U.S. Medicare Part D pressures, Pfizer projects a 6% revenue CAGR from 2025 through 2030. Management is betting that new products and pipeline candidates will substantially offset exclusivity losses over this critical period.

Oncology Wars Heat Up: How Pfizer Stacks Against Rivals

Pfizer ranks among the largest cancer medicine manufacturers, but it faces intense competition from equally heavyweight players. AstraZeneca has positioned oncology as a pillar of its business, now representing around 43% of total revenues. AstraZeneca’s oncology segment surged 16% in the nine-month period of 2025, driven by Tagrisso, Lynparza, Imfinzi, Calquence, and Enhertu (partnered with Daiichi Sankyo).

Merck’s oncology throne is built on two powerhouses: Keytruda (PD-L1 inhibitor) and Lynparza (PARP inhibitor, co-marketed with AstraZeneca). Keytruda alone accounts for over 50% of Merck’s pharmaceutical sales, having recorded $23.3 billion in sales during the first nine months of 2025—up 8% year-over-year.

Bristol-Myers, meanwhile, relies heavily on Opdivo (PD-L1 inhibitor), which comprises roughly 20% of total revenues. Opdivo posted 8% sales growth to $7.54 billion in the nine-month period.

Pfizer’s oncology strategy—anchored by Seagen’s next-generation ADC candidates and its expanding pipeline—positions it as a serious contender in this crowded space.

Stock Valuation: Is PFE Attractive at Current Levels?

Pfizer’s stock has underperformed this year, declining 8% while the broader industry climbed 15.2%. However, the valuation picture tells a different story.

Trading at a forward P/E ratio of 7.76x compared to the industry average of 16.91x, Pfizer appears discounted relative to peers and its own 5-year historical mean of 10.47x. This gap suggests potential upside if the company executes on its growth strategy.

Earnings estimates have seen modest movement. The Zacks Consensus Estimate for 2025 earnings has ticked up from $3.07 to $3.14 per share, while 2026 estimates remain flat at $3.14 (down from a prior $3.15 estimate). The company currently carries a Zacks Rank #3 (Hold) rating.

The Bottom Line

Pfizer’s near-term narrative hinges on one simple equation: can newly acquired and recently launched products grow fast enough to outpace LOE-driven revenue erosion? Early indicators—with 9% operational growth in its pipeline products—suggest the answer is yes. With attractive valuation metrics and a credible path to 6% revenue growth through 2030, Pfizer presents an intriguing case for investors willing to ride out the LOE transition period.